Innova Captab Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ig8hy1x2jakhzjs0mycraxba.pdf

Key Takeaways


CDMO Business: The Price-Volume Disconnect

Lohariwala: "if the pricing impact is on the positive side, then the topline growth will be more than like 15%-20% and the price erosion continue, then it can nullify the volume growth. But overall, as you see, our EBITDA is not linked with the topline. EBITDA is linked with the unit margin."

Jammu Facility: The Margin and Growth Thesis

Lohariwala: "We are expecting since we may be able to claw back some of the incentive to our margin despite passing some of the portion to our customers. So, we are looking at a better margin profile in Jammu as compared to our existing locations."

Sharon Bio-Medicine: A Slow Rebuild


Margin and Financial Health


Customer and Market Dynamics

Lohariwala: "due to this consolidation and free capacity availability, new plant introduction in Jammu with the benefit of GST we are very hopeful and confident to achieve 20%+ CAGR in within this year."

Guidance & Commitments

CommitmentSpecificsTimeline
Jammu plant commercializationAll four blocks to commence operationsQ2 FY25
Jammu revenue ramp-upRevenue to start flowing after commercial production begins4–5 months post-start, i.e., Q3 FY25
Jammu long-term revenue target₹1,000 crore+ from Jammu block3–4 years
CDMO volume growth10%+ double-digit volume growthOngoing
CDMO topline growth15–20% if pricing is positive; flat if price erosion continuesConditional on API price direction
CDMO CAGR target20%+ CAGR in CDMO categoryComing year
API price outlookNo further decline expected; base should stabilizeNext year
Long-term company CAGR20%+ CAGRNext 3–4 years
Sharon accumulated loss set-off~₹20–25 crore tax benefitThis year
General facility utilizationImprovement from current 40–45%Forward-looking, undated

Key Metrics

MetricQ4 FY24
Total income₹268.3 cr, +10.2% YoY
EBITDA₹43.8 cr, +48.7% YoY
EBITDA margin16.7%, vs 12.2% in Q4 FY23
Profit after tax₹28.7 cr, +66.5% YoY
Total income (FY24 full year)₹1,093.8 cr, +16.9% YoY
EBITDA (FY24 full year)₹166.9 cr, +35.9% YoY
PAT (FY24 full year)₹94.3 cr, +38.9% YoY
CDMO revenue contribution53% of total income for the quarter
Domestic branded generics contribution18% of total income for the quarter
International branded generics contribution11% of total income for the quarter
Sharon Bio-Medicine contribution18% of total income for the quarter
CDMO volume growth (FY24)~10%, offset by API price decline
CDMO customer count193 as of FY24
Cephalosporin facility utilization~70%
General facility utilization40%–45%
Sharon Bio-Medicine EBITDA margin~26%–27% for Q4 FY24
Jammu plant gross block~₹460 cr, commercialization expected Q2 FY25
Jammu plant expected annual GST benefit~₹85–₹90 cr
Net cash from operating activities (FY24)₹70–₹75 cr deployed in fixed deposits from internal accruals